Genmab A/S (OTCMKTS:GNMSF) – Equities researchers at Jefferies Financial Group increased their FY2018 earnings per share estimates for shares of Genmab A/S in a research report issued on Friday, September 21st. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of $3.45 for the year, up from their prior estimate of $3.33.

A number of other equities analysts have also recently issued reports on GNMSF. Zacks Investment Research raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 11th. ValuEngine raised shares of Genmab A/S from a “sell” rating to a “hold” rating in a research report on Thursday, July 19th.

GNMSF stock opened at $165.00 on Monday. The stock has a market cap of $10.11 billion, a PE ratio of 61.11 and a beta of 0.28. Genmab A/S has a 1 year low of $143.75 and a 1 year high of $228.00.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Recommended Story: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.